EP0543865A1 - Benzamide derivatives - Google Patents

Benzamide derivatives

Info

Publication number
EP0543865A1
EP0543865A1 EP91914392A EP91914392A EP0543865A1 EP 0543865 A1 EP0543865 A1 EP 0543865A1 EP 91914392 A EP91914392 A EP 91914392A EP 91914392 A EP91914392 A EP 91914392A EP 0543865 A1 EP0543865 A1 EP 0543865A1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
group
carbon
optionally
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91914392A
Other languages
German (de)
French (fr)
Inventor
Andrew William Rhône-Poulenc Rorer Ltd. BRIDGE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Rorer Ltd
Original Assignee
Rhone Poulenc Rorer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Ltd filed Critical Rhone Poulenc Rorer Ltd
Publication of EP0543865A1 publication Critical patent/EP0543865A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/49—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/42—Y being a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

  • This invention relates to new, therapeutically useful benzamide derivatives, to a process for their production and to pharmaceutical compositions
  • the new benzamide derivatives of the present invention are the compounds of formula I, hereinafter depicted, wherein R represents a straight- or branched-chain alkyl group containing up to about 20 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g. oxygen, sulphur or nitrogen atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups,
  • alkoxyalkoxyalkoxyalkyl group optionally carrying one or more substituents selected from halogen, e.g.
  • R 6 represents a hydrogen atom or a methyl group and R 7 represents a methyl, trifluoromethyl or trichloromethyl group, the symbols R 2 are the same or different and each represents a hydrogen atom, a straight- or
  • R 3 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to about 6 carbon atoms
  • R 4 represents a straight- or
  • R 5 represents a group of the formula -NR 8 R 9 or -OR 10 wherein R 8 and R 9 may be the same or different and each represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g.
  • R 10 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and
  • hetero atoms e.g. oxygen, sulphur or nitrogen atoms
  • sulphinyl or sulphonyl groups optionally interrupted by one or more sulphinyl or sulphonyl groups, and pharmaceutically acceptable salts thereof .
  • R 1 represents an alkyl, alkenyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkoxyalkoxyalkoxyalkyl or
  • haloalkyl e.g. chloroalkyl, group, containing from 8 to 20 carbon atoms, preferably an alkyl or alkenyl group containing from 8 to 20, preferably 10 to 18, carbon atoms;
  • R 3 represents a hydrogen atom
  • R 4 represents an imidazol-1-yl group or a
  • alkoxy or alkylthio group containing up to 3, preferably 1 or 2, carbon atoms, preferably methoxy, methylthio or ethylthio;
  • R 8 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to 3 carbon atoms, e.g. methyl;
  • R 9 represents a straight- or branched-chain
  • alkylthioalkyl group containing 3 or 4 carbon atoms or an alkenyl group containing 5 carbon atoms, e.g. a butyl, methoxyethyl,
  • R 10 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to 6, preferably up to 3, carbon atoms, e.g. methyl; the other symbols being as hereinbefore defined, and pharmaceutically acceptable salts thereof.
  • Important compounds according to the invention include:- A (Z)-N-(2-methylthio)ethyl-4-methylthio-3- (octadec-9-enamido)benzamide ;
  • BC 4-ethylthio-N-(3-methyIthiopropyl)-3-(5,9- dioxaoctadecanamido)benzamide;
  • BE 4-ethylthio-N-(3-methyIthiopropyl)-3-(6,10,14- trioxahexadecanamido)benzamide;
  • BF 4-imidazol-1-yl-N-(3-methyIthiopropyl)-3-(5- oxahexadecanamido)benzamide;
  • the compounds according to the invention are inhibitors of acyl coenzyme-A:cholesterol-O-acyl transferase (ACAT;EC 2.3.1.26). They are therefore of value as anti-atherosclerotic agents and have utility in the treatment of atherosclerosis,
  • hyperlipidaemia hyperlipidaemia, cholesterol ester storage disease and atheroma in vein grafts.
  • alkoxycarbonyloxy group for example methoxycarbonyloxy or ethoxycarbonyloxy, or with the corresponding
  • R 1 and R 2 are as hereinbefore defined.
  • the reaction may be performed in the presence of a suitable base, such as a tertiary amine, e.g. triethylamine or
  • reaction may be carried out in a suitable solvent, e.g. dichloromethane, optionally with heating.
  • a suitable solvent e.g. dichloromethane
  • compounds of formula I wherein R is other than hydrogen are prepared by reacting a compound of general formula:
  • R 11 represents a straight- or branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g. oxygen, sulphur or nitrogen atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups, or a compound of general formula:
  • R 1 , R 2 , R 3 and R 4 are as hereinbefore defined and Z 2 represents a hydroxy group, a halogen, e.g. chlorine, atom or an alkoxycarbonyloxy group, for example
  • reaction conditions are similar to those described above for the reaction between the compounds of general formulae II and III.
  • reaction is preferably performed in the presence of a condensing agent, such as dicyclohexylcarbodiimide, or a catalytic quantity of an inorganic acid, e.g. hydrochloric acid, optionally prepared in situ.
  • a condensing agent such as dicyclohexylcarbodiimide
  • a catalytic quantity of an inorganic acid e.g. hydrochloric acid
  • reaction may be carried out in a suitable solvent, e.g. dichloromethane, optionally with heating.
  • a suitable solvent e.g. dichloromethane
  • compounds of general formula I are prepared by the interconversion of other compounds of formula I.
  • compounds of general formula I are prepared by the interconversion of other compounds of formula I.
  • R 8 and/or R 9 is other than a hydrogen atom are prepared from compounds of formula I wherein R 3 and/or R 8 and/or R 9 represents a hydrogen atom by the application or adaptation of known methods of alkylation; according to a further feature of the invention, (b) compounds of formula I containing a sulphonyl group are prepared by the oxidation of compounds of formula I containing a sulphinyl or thio group and compounds of formula I containing a sulphinyl group are prepared by the
  • compounds of formula I wherein R 10 represents a hydrogen atom are prepared from compounds of formula I wherein R 10 represents a straight- or branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g.
  • branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g. oxygen, sulphur or nitrogen atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups are prepared by the esterification of compounds of formula I wherein R 10 represents a hydrogen atom, by the application or adaptation of known methods.
  • pharmaceutically acceptable salts as used in this specification is meant acid addition salts the anions of which are relatively innocuous to the animal organism when used in therapeutic doses so that the beneficial pharmaceutical properties of the compounds of formula I are not vitiated by
  • pharmaceuticals may be selected from salts derived from inorganic acids, for example hydrochlorides,
  • hydrobromides hydrobromides, phosphates, sulphates and nitrates, and organic acids, for example oxalates, lactates,
  • salts of the compounds of formula I are useful for the purposes of purification of the parent compounds, for example by exploitation of the
  • the salts can be prepared from the parent compounds of formula I by the application or adaptation of known methods, and the parent compounds of formula I can be prepared from the salts by the application or adaptation of known methods.
  • the compounds of formula I can be purified by the usual physical means, for example by
  • acid halides of formula VII wherein Z 1 represents a halogen atom may be prepared from the corresponding carboxylic acids of formula VII wherein Z 1 represents a hydroxy group by the application or adaptation of known methods, e.g., when Z 1 represents a chlorine atom, by reaction with thionyl chloride or oxalyl chloride.
  • acid halides of formula III wherein Z 1 represents a halogen atom may be prepared from the corresponding carboxylic acids of the general formula:-
  • R 1 and R 2 are as hereinbefore defined, by the application or adaptation of known methods, e.g., when
  • Z 1 represents a chlorine atom, by reaction with thionyl chloride or oxalyl chloride.
  • alkoxyalkyl or, more particularly, an alkoxyalkoxyalkyl or, especially, an alkoxyalkoxyalkoxyalkyl, group, and
  • R 2 is as hereinbefore defined, are key intermediates and they, a process for their preparation, and their use in synthesis of useful pharmaceuticals, e.g.
  • compounds of formula IX are prepared by the oxidation of compounds of the general formula:-
  • R 12 and R 2 are as hereinbefore defined, by the application or adaptation of known methods, for example by reaction with an alkali metal halite such as sodium bromite and a free radical such as 2,2,6,6-tetramethyl- 1-piperidinyloxy free radical.
  • an alkali metal halite such as sodium bromite
  • a free radical such as 2,2,6,6-tetramethyl- 1-piperidinyloxy free radical.
  • This reaction is preferably carried out in the presence of a base such as an aqueous solution of an alkali metal carbonate or bicarbonate, and in the presence of a suitable solvent such as acetonitrile, preferably at or, more especially below room
  • a base such as an aqueous solution of an alkali metal carbonate or bicarbonate
  • a suitable solvent such as acetonitrile
  • aminobenzamide derivative there were prepared:- N-butyl-3-hexadecanamido-4-(methylthio)benzamide, in the form of. white crystals, m.p. 125-126°C [Elemental analysis:- C,70.4;H,10.18;N,5.88;S,6.95%; calculated:- C, 70.54 ; H, 10.15 ; N, 5.88 ; S , 6.73%] ;
  • the mixture was stirred at the ambient temperature for 1 hour, then it was diluted with dichloromethane (100ml) and washed sequentially with hydrochloric acid (100ml;1N), aqueous sodium chloride solution (100ml), aqueous potassium hydroxide solution (1.5g in 100ml), hydrochloric acid (100ml;1N) and with aqueous sodium chloride solution (100ml), dried over magnesium sulphate and concentrated under reduced pressure.
  • Example 3 sodium hydroxide (0.6g), water (20ml) and ethanol (200ml) was heated at reflux for 1.5 hours.
  • the mixture [containing (Z)-sodium 4-methoxy-3-(octadec-9-enamido)benzoate] was cooled to the ambient temperature and was then poured onto a mixture of crushed ice and concentrated hydrochloric acid.
  • the product was collected and recrystallised from methanol, to give (Z)-4-methoxy-3-(octadec-9-enamido)benzoic acid (4.14g) in the form of a white powder, m.p.
  • N-butyl-3-octadecanamido-4-(methylthio)benzamide in the form of a white powder, m.p. 115-118°C (from a mixture of t-butyl methyl ether and methanol)
  • N-butyl-3-(5-chloropentanamido)-4-(ethylthio)benzamide in the form of a white powder, m.p. 104-105°C (from t-butyl methyl ether) [Elemental analysis:- C,58.2;
  • N-butyl-4-ethylthio-3-(5,9-dioxahexadecanamido)-benzamide in the form of a pale brown oil (eluting with a mixture of dichloromethane and methanol)
  • N-butyl-4-methylthio-3-(5-oxahexadecanamido)benzamide in the form of a pale brown oil that solidified on standing (eluting with a mixture of dichloromethane and methanol) [Elemental analysis:- C,68.0;H,9.9;N,5.6; S,6.24%; calculated:- C, 67.74;H,9.69;N,5.85;S,6.70%]; 4-methoxy-N-(3-methyIthiopropyl)-3-(5,9-dioxahexadecanamido)benzamide, in the form of a pale brown oil (eluting with a mixture of dichloromethane and
  • 5-oxahexadecanoic acid in the form of a colourless, mobile oil which solidified, m.p. 28-30°C [Elemental analysis:- C,68.5;H,11.6%; calculated:-C,69.72;H,11.70%].
  • Methyl 4-(imidazol-1-yl)-3-nitrobenzoate (19.3g) was reduced by reaction with iron powder (22. Og) in boiling ethanol (150ml) containing water (35ml) and hydrochloric acid (1.5ml;1N). Recrystallisation from ethyl acetate gave methyl 3-amino-4-(imidazol-1-yl)-benzoate (9.7g) in the form of pale yellow crystals, m.p. 161-165°C.
  • the present invention also includes within its scope pharmaceutical formulations which comprise at least one of the compounds of formula I, or a
  • the compounds of the present invention may be administered parenterally, rectally or orally.
  • Solid compositions for oral administration include compressed tablets, pills, powders and
  • one or more of the active compounds is, or are, admixed with at least one inert diluent such as starch, sucrose or lactose.
  • the compositions may also comprise, as is normal practice,, additional substances other than inert diluents, e.g. lubricating agents, such as magnesium stearate.
  • Liquid compositions for oral administration include pharmaceutically acceptable emulsions,
  • compositions according to the invention for oral administration also include capsules of absorbable material such as
  • gelatin containing one or more of the active
  • Preparations according to the invention for parenteral administration include sterile aqueous, aqueous-organic, and organic solutions, suspensions and emulsions.
  • organic solvents or suspending media are propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate.
  • the compositions may also contain adjuvants such as stabilising, preserving, wetting, emulsifying and dispersing agents. They may be sterilised, for example, by filtration through a bacteria-retaining filter, by incorporation in the compositions of sterilising agents, by irradiation or by heating. They may also be manufactured in the form of sterile solid compositions, which can be dissolved in sterile water or some other sterile injectable medium immediately before use.
  • Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of formula I.
  • compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired
  • the doses are generally from about 0.5 to about 70, preferably about 1 to about 10, mg/kg body weight per day by oral administration.
  • No. 2 size gelatin capsules each containing:- N-butyl-3-hexadecanamido-4-(methylthio)- benzamide; 20 mg lactose 100 mg starch 60 mg dextrin 40 mg magnesium stearate 1 mg were prepared in accordance with the usual procedure.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Dérivé de benzamide de formule (I) où R1 représente un alkyle contenant éventuellement une ou plusieurs liaison(s) double(s) ou triple(s) carbone-carbone, et éventuellement interrompu par un ou plusieurs hétéroatome(s) ou des groupes sulfinyles ou sulfonyles, portant éventuellement un ou plusieurs substituants choisis à partir de groupes halogène, amino, alcoxy, alkylthio, alkylamino ou -CONR6R7, où R6 représente hydrogène ou méthyle et R7 représente méthyle, trifluorométhyle ou trichlorométhyle, les symboles R2 représentent hydrogène, alkyle ou phényle éventuellement substitué ou les deux groupes R2 forment un cycle, R3 représente hydrogène ou alkyle, R4 représente alcoxy, alkylthio, diméthylamino ou un groupe hétérocyclo à 5 ou 8 membres, et R5 représente -NR8R9 ou -OR10, où R8 et R9 représentent hydrogène ou alkyle contenant éventuellement une ou plusieurs liaison(s) double(s) ou triple(s) carbone-carbone, et éventuellement interrompus par un ou plusieurs hétéroatome(s), ou des groupes sulfinyles ou sulfonyles, et R10 représente hydrogène ou alkyle contenant éventuellement une ou plusieurs liaison(s) double(s) ou triple(s) carbone-carbone, et éventuellement interrompu par un ou plusieurs hétéroatome(s), ou des groupes sulfinyle ou sulfonyle. Ce dérivé et des sels pharmaceutiquement acceptables de celui-ci présentent des caractéristiques pharmacologiques utiles.Benzamide derivative of formula (I) where R1 represents an alkyl optionally containing one or more carbon-carbon double or triple bond (s), and optionally interrupted by one or more heteroatom (s) or sulfinyl groups or sulfonyls, optionally carrying one or more substituents chosen from halogen, amino, alkoxy, alkylthio, alkylamino or -CONR6R7 groups, where R6 represents hydrogen or methyl and R7 represents methyl, trifluoromethyl or trichloromethyl, the symbols R2 represent hydrogen, alkyl or optionally substituted phenyl or the two groups R2 form a ring, R3 represents hydrogen or alkyl, R4 represents alkoxy, alkylthio, dimethylamino or a heterocyclo group with 5 or 8 members, and R5 represents -NR8R9 or -OR10, where R8 and R9 represent hydrogen or alkyl optionally containing one or more carbon-carbon double or triple bond (s), and optionally interrupted by one or more heteroatom (s), or groups pes sulfinyles or sulfonyles, and R10 represents hydrogen or alkyl possibly containing one or more double bond (s) or triple (s) carbon-carbon, and possibly interrupted by one or more heteroatom (s), or sulfinyl groups or sulfonyl. This derivative and pharmaceutically acceptable salts thereof have useful pharmacological characteristics.

Description

BENZAMIDE DERIVATIVES
This invention relates to new, therapeutically useful benzamide derivatives, to a process for their production and to pharmaceutical compositions
containing them, and methods for their use.
The new benzamide derivatives of the present invention are the compounds of formula I, hereinafter depicted, wherein R represents a straight- or branched-chain alkyl group containing up to about 20 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g. oxygen, sulphur or nitrogen atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups,
preferably an alkylthioalkyl, alkylaminoalkyl or dialkylaminoalkyl group or more especially an alkyl, alkenyl, alkoxyalkyl, alkoxyalkoxyalkyl, or
alkoxyalkoxyalkoxyalkyl group, optionally carrying one or more substituents selected from halogen, e.g.
bromine, iodine, fluorine or, preferably, chlorine, atoms, amino groups, alkoxy, alkylthio and alkylamino groups each containing up to about 3 carbon atoms, and groups of the formula -CONR6R7 wherein R6 represents a hydrogen atom or a methyl group and R7 represents a methyl, trifluoromethyl or trichloromethyl group, the symbols R2 are the same or different and each represents a hydrogen atom, a straight- or
branched-chain alkyl group containing up to about 6 carbon atoms or an optionally substituted phenyl group or the two groups R2 together with the carbon atom to which they are attached form a saturated or unsaturated ring containing from 3 to about 8 carbon atoms and optionally containing one or more
hetero atoms selected from oxygen, sulphur and nitrogen atoms, R3 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to about 6 carbon atoms, R4 represents a straight- or
branched-chain alkoxy or alkylthio group containing up to about 6 carbon atoms or a dimethylamino group or a
5- to 8-membered heterocyclo group containing at least one nitrogen atom and linked via that nitrogen atom to the rest of the molecule, e.g. an imidazol-1-yl or pyrrolidin-1-yl group, and R5 represents a group of the formula -NR8R9 or -OR10 wherein R8 and R9 may be the same or different and each represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g. oxygen, sulphur or nitrogen atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups, and R10 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and
optionally interrupted by one or more hetero atoms, e.g. oxygen, sulphur or nitrogen atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups, and pharmaceutically acceptable salts thereof .
As will be apparent to those skilled in the art, some of the compounds of formula I exhibit optical isomerism. All such forms, and their mixtures, and processes for their preparation and separation, are embraced by the invention.
Especially important compounds of the present invention include those wherein at least one of the symbols has a value selected from the following:- (i) R1 represents an alkyl, alkenyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkoxyalkoxyalkoxyalkyl or
haloalkyl, e.g. chloroalkyl, group, containing from 8 to 20 carbon atoms, preferably an alkyl or alkenyl group containing from 8 to 20, preferably 10 to 18, carbon atoms;
(n ..) the symbols R2 each represent a hydrogen atom, or the two groups R2 together with the carbon atom to which they are attached form a
cycloalkyl ring containing from 3 to 8,
preferably 5 or 6, e.g. 5, carbon atoms; (iii) R3 represents a hydrogen atom;
(iv) R4 represents an imidazol-1-yl group or a
straight- or branched-chain alkoxy or alkylthio group containing up to 3, preferably 1 or 2, carbon atoms, preferably methoxy, methylthio or ethylthio;
(v) R8 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to 3 carbon atoms, e.g. methyl;
(vi) R9 represents a straight- or branched-chain
alkyl or alkenyl group containing up to 6 carbon atoms, optionally interrupted by one or more oxygen or sulphur atoms or sulphonyl groups, preferably an alkyl, alkoxyalkyl or
alkylthioalkyl group containing 3 or 4 carbon atoms, or an alkenyl group containing 5 carbon atoms, e.g. a butyl, methoxyethyl,
methylthioethyl, methoxypropy1,
methylthiopropy1, methylsulphonylpropyl or methylbut-2-enyl group;
(vii) R10 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to 6, preferably up to 3, carbon atoms, e.g. methyl; the other symbols being as hereinbefore defined, and pharmaceutically acceptable salts thereof.
Important compounds according to the invention include:- A (Z)-N-(2-methylthio)ethyl-4-methylthio-3- (octadec-9-enamido)benzamide ;
B (Z)-N-(2-methoxy)ethyl-4-methylthio-3-(octadec- 9-enamido)benzamide;
C (Z)-methyl 4-methoxy-3-(octadec-9-enamido)- benzoate;
D N-(2-methylthio)ethyl-3-hexadecanamido-4- (methylthio)benzamide;
E N-butyl-3-hexadecanamido-4-(methylthio)benzamide; F N-(2-methoxy)ethyl-3-hexadecanamido-4-(methylthio)benzamide;
G N-butyl-3-dodecanamido-4-(methylthio)benzamide; H N-(2-methoxy)ethyl-3-dodecanamido-4-(methylthio)benzamide;
I N-(2-methylthio)ethyl-3-dodecanamido-4-(methylthio)benzamide;
J N-butyl-N-methyl-3-hexadecanamido-4-methoxybenzamide;
K (Z)-N-butyl-4-methoxy-3-(octadec-9-enamido)- benzamide;
L N-(2-methylthio)ethyl-3-(1-decylcyclopentanecarboxamido)-4-(methylthio)benzamide;
M (Z)-sodium 4-methoxy-3-(octadec-9-enamido)- benzoate;
N (Z)-4-methoxy-3-(octadec-9-enamido)benzoic
acid; O N-butyl-3-dodecanamido-4-(ethylthio)benzamide; P N-butyl-4-ethylthio-3-hexadecanamidobenzamide; Q N-butyl-4-ethylthio-3-heptadecanamidobenzamide; R N-butyl-4-ethylthio-3-octadecanamidobenzamide; S 4-ethylthio-3-hexadecanamido-N-(2-methylthioethyl)benzamide;
T 4-ethylthio-3-heptadecanamido-N-(2-methylthioethyl)benzamide;
U 3-heptadecanamido-4-methylthio-N-(2-methylthioethyl)benzamide;
V 3-heptadecanamido-N-(2-methoxyethyl)-4-(methylthio)benzamide;
W (z)-N-butyl-3-octadec-9-enamido-4-(methylthio)- benzamide;
X 4-ethylthio-N-(3-methylthiopropyl)-3-octadecanamidobenzamide;
Y 4-ethylthio-3-heptadecanamido-N-(3-methylthiopropyl)benzamide;
Z 4-ethylthio-3-hexadecanamido-N-(3-methylthiopropyl)benzamide;
AA 4-methylthio-N-(2-methylthioethyl)-3-octadecanamidobenzamide;
AB N-butyl-3-dodecanamido-4-methoxybenzamide;
AC 4-ethylthio-3-hexadecanamido-N-(3-methoxypropyl)benzamide;
AD N-butyl-3-octadecanamido-4-(methylthio)- benzamide;
AE 4-methylthio-N-(3-methylthiopropyl)-3-octadecanamidobenzamide;
AF 4-ethylthio-N-(3-methoxypropyl)-3-octadecanamidobenzamide;
AG N-butyl-3-(5-chloropentanamido)-4-(ethylthio)benzamide;
AH 3-(4-chlorobutanamido)-4-ethylthio-N-(3-methylthiopropyl)benzamide;
AI 3-(5-chloropentanamido)-4-ethylthio-N-(3-methylthiopropyl)benzamide;
AJ methyl 3-hexadecanamido-4-methoxybenzoate;
AK 3-hexadecanamido-4-methoxybenzoic acid;
AL sodium 3-hexadecanamido-4-methoxybenzoate;
AM 3-hexadecanamido-4-methoxy-N-(2-methoxyethyl)- benzamide;
AN 3-hexadecanamido-4-methoxy-N-(3-methylbut-2- enyl)benzamide;
AO N-butyl-4-methylthio-3-(5,9-dioxahexadecanamido)benzamide;
AP 4-methylthio-N-(3-methylthiopropyl)-3-(5,9- dioxahexadecanamido)benzamide;
AQ N-butyl-4-ethylthio-3-(5,9,13-trioxahexadecanamido)benzamide;
AR 4-ethylthio-N-(3-methylthiopropyl)-3-(5,9- dioxahexadecanamido)benzamide; AS N-butyl-4-ethylthio-3-(5,9-dioxahexadecanamido)benzamide;
AT 4-ethylthio-N-(3-methoxypropyl)-3-(5,9-dioxahexadecanamido)benzamide;
AU 4-ethylthio-N-(3-methoxypropyl)-3-(5,9,13- trioxahexadecanamido)benzamide;
AV 4-ethylthio-N-(3-methoxypropyl)-3-(5-oxahexadecanamido)benzamide;
AW 4-methylthio-N-(3-methyIthiopropyl)-3-(5- oxahexadecanamido)benzamide;
AX N-butyl-4-methylthio-3-(5-oxahexadecanamido)- benzamide;
AY 4-methoxy-N-(3-methylthiopropyl)-3-(5,9-dioxahexadecanamido)benzamide;
AZ 4-ethylthio-N-(3-methyIthiopropyl)-3-(5,9,13- trioxahexadecanamido)benzamide;
BA methyl 3-heptadecanamido-4-(imidazol-1-yl)- benzoate;
BB N-(3-methylsulphonylpropyl)-4-methylthio-3- (5,9-dioxahexadecanamido)benzamide;
BC 4-ethylthio-N-(3-methyIthiopropyl)-3-(5,9- dioxaoctadecanamido)benzamide;
BD N-butyl-4-ethylthio-3-(5,10-dioxahexadecanamido)benzamide;
BE 4-ethylthio-N-(3-methyIthiopropyl)-3-(6,10,14- trioxahexadecanamido)benzamide; BF 4-imidazol-1-yl-N-(3-methyIthiopropyl)-3-(5- oxahexadecanamido)benzamide; and
BG 3-hexadecanamido-4-imidazol-1-yl-N-(3- methyIthiopropyl)benzamide.
The letters A to BG are allocated to compounds for easy reference later in this specification.
The compounds according to the invention are inhibitors of acyl coenzyme-A:cholesterol-O-acyl transferase (ACAT;EC 2.3.1.26). They are therefore of value as anti-atherosclerotic agents and have utility in the treatment of atherosclerosis,
hyperlipidaemia, cholesterol ester storage disease and atheroma in vein grafts.
Compounds within the scope of the present invention exhibit positive pharmacological activities as demonstrated by the following in vitro and in-vivo tests which are believed to correlate to
pharmacological activity in humans and other animals.
In assays performed in vitro microsomes (prepared from the livers of rats fed a diet
supplemented with 0.5%w/w cholesterol and 0.25%w/w cholic acid for 7 days) were incubated with
radiolabelled oleoyl-CoA in the presence of compounds according to the invention at a concentration of
0.5μg/ml or 1μg/ml. The degree of ACAT inhibition produced was up to 99%. in in-vivo tests, using rats fed on a diet similar to that described above and supplemented further by 0.01%w.w of test compound, compounds according to the invention inhibited increases in plasma cholesterol concentrations, measured after 3 days, relative to control animals fed on the
cholesterol supplemented diet without the drug, by up to 100%.
Compounds of formula I can be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature.
According to a feature of the present invention, compounds of general formula I are prepared by the reaction of a compound of general formula II
hereinafter depicted, wherein R3, R4 and R5 are as hereinbefore defined, with a compound of the general formula:
R1-C(R2)2COZ1 (III) wherein R1 and R2 are as hereinbefore defined and Z1 represents a halogen, e.g. chlorine, atom or an
alkoxycarbonyloxy group, for example methoxycarbonyloxy or ethoxycarbonyloxy, or with the corresponding
anhydride of the general formula:
[R1-C(R2)2CO]2O (IV)
wherein R1 and R2 are as hereinbefore defined.
When Z1 represents a halogen atom the reaction may be performed in the presence of a suitable base, such as a tertiary amine, e.g. triethylamine or
pyridine.
In each instance the reaction may be carried out in a suitable solvent, e.g. dichloromethane, optionally with heating. According to a further feature of the invention, compounds of formula I wherein R is other than hydrogen are prepared by reacting a compound of general formula:
R11OH (V)
wherein R11 represents a straight- or branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g. oxygen, sulphur or nitrogen atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups, or a compound of general formula:
HNR8R9 (VI)
wherein R8 and R9 are as hereinbefore defined, with a compound of formula VII, hereinafter depicted, wherein
R1, R2, R3 and R4 are as hereinbefore defined and Z2 represents a hydroxy group, a halogen, e.g. chlorine, atom or an alkoxycarbonyloxy group, for example
methoxycarbonyloxy or ethoxycarbonyloxy, or with the corresponding anhydride .
The reaction conditions are similar to those described above for the reaction between the compounds of general formulae II and III.
When Z2 represents a hydroxy group the reaction is preferably performed in the presence of a condensing agent, such as dicyclohexylcarbodiimide, or a catalytic quantity of an inorganic acid, e.g. hydrochloric acid, optionally prepared in situ.
In each instance the reaction may be carried out in a suitable solvent, e.g. dichloromethane, optionally with heating.
According to a further feature of the invention, compounds of general formula I are prepared by the interconversion of other compounds of formula I. For example, according to a feature of the invention,
(a) compounds of formula I wherein R3 and/or
R8 and/or R9 is other than a hydrogen atom are prepared from compounds of formula I wherein R3 and/or R8 and/or R 9 represents a hydrogen atom by the application or adaptation of known methods of alkylation; according to a further feature of the invention, (b) compounds of formula I containing a sulphonyl group are prepared by the oxidation of compounds of formula I containing a sulphinyl or thio group and compounds of formula I containing a sulphinyl group are prepared by the
oxidation of compounds of formula I containing a thio group using a conventional oxidant, such as a
percarboxslic acid (e.g. m-chloroperbenzoic acid), in an inert solvent, such as dichloromethane, at or below room temperature; according to a further feature of the invention, (c) compounds of formula I wherein R10 represents a hydrogen atom are prepared from compounds of formula I wherein R10 represents a straight- or branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g. oxygen, sulphur or nitrogen atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups, by hydrolysis of the ester grouping -COOR10 by known methods, for example by reaction with alkali, e.g.
aqueous sodium hydroxide solution, followed by
neutralisation by treatment with mineral acid, e.g. dilute hydrochloric acid; and, conversely, according to a further feature of the invention, (d) compounds of formula I wherein R10 represents a straight- or
branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g. oxygen, sulphur or nitrogen atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups are prepared by the esterification of compounds of formula I wherein R10 represents a hydrogen atom, by the application or adaptation of known methods.
By the term "pharmaceutically acceptable salts" as used in this specification is meant acid addition salts the anions of which are relatively innocuous to the animal organism when used in therapeutic doses so that the beneficial pharmaceutical properties of the compounds of formula I are not vitiated by
side-effects ascribable to those anions and salts formed with bases such as alkali metal, e.g. sodium or potassium, salts and alkaline earth metal, e.g. calcium or magnesium, salts, the cations of which are
relatively innocuous to the animal organism when used in therapeutic doses so that the beneficial
pharmaceutical properties of the compounds of formula I are not vitiated by side-effects ascribable to those cations.
It is to be understood that, where in this specification reference is made to the compounds of formula I, it is intended to refer also, where the context so permits, to their pharmaceutically
acceptable salts.
Suitable acid addition salts for use in
pharmaceuticals may be selected from salts derived from inorganic acids, for example hydrochlorides,
hydrobromides, phosphates, sulphates and nitrates, and organic acids, for example oxalates, lactates,
tartrates, acetates, salicylates, citrates,
propionates, succinates, furmarates, maleates,
methylene-bis-β-hydroxynaphthoates, gentisates and di-p-toluoyltartrates. As well as being useful in themselves as active compounds, salts of the compounds of formula I are useful for the purposes of purification of the parent compounds, for example by exploitation of the
solubility differences between the salts and the parent compound, by techniques well known to those skilled in the art.
The salts can be prepared from the parent compounds of formula I by the application or adaptation of known methods, and the parent compounds of formula I can be prepared from the salts by the application or adaptation of known methods.
The compounds of formula I can be purified by the usual physical means, for example by
crystallisation or chromatography.
Compounds of formulae II, III, IV, V, VI and VII may be prepared by the application or adaptation of known methods.
For example, acid halides of formula VII wherein Z1 represents a halogen atom may be prepared from the corresponding carboxylic acids of formula VII wherein Z1 represents a hydroxy group by the application or adaptation of known methods, e.g., when Z1 represents a chlorine atom, by reaction with thionyl chloride or oxalyl chloride. Similarly, acid halides of formula III wherein Z1 represents a halogen atom may be prepared from the corresponding carboxylic acids of the general formula:-
R1-C(R2)2COOH (VIII)
wherein R1 and R2 are as hereinbefore defined, by the application or adaptation of known methods, e.g., when
Z1 represents a chlorine atom, by reaction with thionyl chloride or oxalyl chloride.
Compounds of the general formula:-
R12-C(R2)2COOH (IX)
within formula VIII, wherein R12 represents an
alkoxyalkyl or, more particularly, an alkoxyalkoxyalkyl or, especially, an alkoxyalkoxyalkoxyalkyl, group, and
R2 is as hereinbefore defined, are key intermediates and they, a process for their preparation, and their use in synthesis of useful pharmaceuticals, e.g.
compounds of formula I, form features of the present invention.
According to a feature of this invention, compounds of formula IX are prepared by the oxidation of compounds of the general formula:-
R12-C(R2)2CH2OH (X)
wherein R12 and R2 are as hereinbefore defined, by the application or adaptation of known methods, for example by reaction with an alkali metal halite such as sodium bromite and a free radical such as 2,2,6,6-tetramethyl- 1-piperidinyloxy free radical.
This reaction is preferably carried out in the presence of a base such as an aqueous solution of an alkali metal carbonate or bicarbonate, and in the presence of a suitable solvent such as acetonitrile, preferably at or, more especially below room
temperature.
The following Examples illustrate the
preparation of the compounds according to the
invention. Examples 1 to 16 illustrate the
preparation of compounds of general formula I, Examples 17 and 18 illustrate the preparation of key
intermediates of general formula IX, and the Reference Examples illustrate the preparation of other
intermediates.
EXAMPLE 1
Compound A
A stirred solution of oleic acid (4.20g) and triethylamine (1.8g) in dichloromethane (50ml was treated with methyl chloroformate (1.7g) at -30°C.
The mixture was stirred for 2 hours, allowing it to warm to the ambient temperature. It was then treated with a solution of N-(2-methylthio)ethyl-4-methylthio- 3-aminobenzamide (4.0g) and triethylamine (2.5g) in dichloromethane (50ml). The resulting clear solution was left to stand for 17 hours and was then diluted with dichloromethane (250ml), washed sequentially with hydrochloric acid (200ml;1N), aqueous sodium chloride solution, saturated aqueous sodium hydrogen carbonate solution (100ml) and finally with aqueous sodium
chloride solution, dried over magnesium sulphate and concentrated under reduced pressure. The resulting residue was dissolved in diethyl ether (250ml) and the solution was washed with hydrochloric acid
(2x150ml;2N), dried over magnesium sulphate and
concentrated under reduced pressure. The resulting residue was crystallised from a mixture of petrol
(b.p. 40-60°C) and diethyl ether, to give a waxy solid, which was subjected to column chromatography on silica gel, eluting with ethyl acetate, and recrystallised from t-butyl methyl ether, to give (Z)-N-(2-methylthio) ethyl-4-methylthio-3-(octadec-9-enamido) benzamide (0.7g) in the form of a colourless, soft solid, m.p. 84-86°C. [Elemental analysis:-C,67.4;H,9.5;N,5.1; S,12.2%; calculated:- C,66.88;H,9.29;N,5.38;S,12.31%].
EXAMPLE 2
Compound B
An ice-cooled solution of N-(2-methoxy)ethyl-3-amino-4-(methylthio)benzamide (3.99g) in dry dichloromethane (50ml) and dry triethylamine (2.79ml) was slowly treated with a solution of oleoyl chloride (5g) in dry dichloromethane (30ml). The mixture was stirred at the ambient temperature for 2.5 hours and was then concentrated under reduced pressure, to leave a solid. This solid was dissolved in ethyl acetate and the solution was washed sequentially with
hydrochloric acid (2N), aqueous sodium hydroxide
solution (1N) and with water, dried over magnesium sulphate and concentrated under reduced pressure. The resulting residue was crystallised from a mixture of amyl acetate (65ml) and ethyl acetate (5ml), and then from toluene, to give (Z)-N-(2-methoxy)ethyl-4- methylthio-3-(octadec-9-enamido) benzamide (4.81g) in the form of a soft, white solid, m.p. 110-112°C.
[Elemental analysis:- C,69.1;H,9.8;N,5.46;S 6.5%;
calculated:- C,69.00;H,9.58;N,5.55;S,6.35%].
EXAMPLE 3
Compound C
A solution of methyl 3-amino-4-methoxybenzoate (3.0g) in dry dichloromethane (50ml) and dry
triethylamine (2.79ml) was slowly treated with a solution of oleoyl chloride (5g) in dry dichloromethane (30ml). The mixture was stirred at the ambient temperature for 45 minutes and was then concentrated under reduced pressure. The resulting solid was crystallised from aqueous ethanol, to give brown crystals (6.63g), of which a sample (250mg) was
recrystallised from ice-cold petrol (b.p. 40-60°C) containing a trace of methanol, to give (Z) -methyl 4-methoxy-3-(octadec-9-enamido)benzoate (195mg), in the form of off-white crystals, m.p. 46-47°C. [Elemental analysis:- C,72.2;H,9.65;N,3.18%; calculated:- C,72.77; H,9.72;N,3.14%]. EXAMPLE 4
Compound K
A stirred, ice-cooled solution of (Z)-4-methoxy- 3-(octadec-9-enamido)benzoyl chloride (1.5g) [prepared by the reaction of thionyl chloride with (Z)-4-methoxy- 3-(octadec-9-enamido)benzoic acid (itself prepared as described hereinafter in Example 7)] in dichloromethane (20ml) was treated with a solution of butylamine (0.5g) in dry dichloromethane (10ml). The mixture was stirred at the ambient temperature for 1 hour and was then concentrated under reduced pressure. The resulting residue was crystallised from cyclohexane and then recrystallised from a mixture of diethyl ether and pentane to give (Z)-N-butyl-4-methoxy-3-(octadec-9- enamido)benzamide (0.474g) in the form of a grey solid, m.p. 81-82°C. [Elemental analysis:- C,73.9;H,10.4; N,5.7%; calculated:- C,74.03;H,10.35;N,5.76%].
EXAMPLE 5
Compounds D, E, F, G, H, I and J
A solution of N-(2-methylthio)ethyl-3-amino-4- (methylthio)benzamide (3.0g) and dry triethylamine
(3.0g) in dry dichloromethane (50ml) was treated with a solution of hexadecanoyl chloride (3.4g) in dry
dichloromethane (20ml). The solution was stirred at the ambient temperature for 3 hours and was then
diluted with dichloromethane (250ml). The solution was washed with hydrochloric acid (100ml;1N), dried over magnesium sulphate and concentrated under reduced pressure, and the resulting solid was recrystallised from a mixture of t-butyl methyl ether and ethanol (9:lv/v), to give N-(2-methylthio)ethyl-3-hexadecanamido-4-(methylthio)benzamide (5.14g) in the form of white crystals, m.p. 104-105°C. [Elemental
analysis:- C,65.3;H,9.4;N,5.6;S,13.2%; calculated:- C, 65.54 ; H, 9.37 ; N, 5. 66 ; S, 12.96%] .
By proceeding in a similar manner, but using the appropriate acid chloride and the appropriate
aminobenzamide derivative, there were prepared:- N-butyl-3-hexadecanamido-4-(methylthio)benzamide, in the form of. white crystals, m.p. 125-126°C [Elemental analysis:- C,70.4;H,10.18;N,5.88;S,6.95%; calculated:- C, 70.54 ; H, 10.15 ; N, 5.88 ; S , 6.73%] ;
N-(2-methoxy)ethyl-3-hexadecanamido-4-(methylthio)-benzamide in the form of white crystals, m.p. 115117ºC [Elemental analysis:- C,68.1;H,9.9;N,5.8;S,6.88%; calculated: - C,67.74;H,9.69;N,5.85;S,6.70%];
N-butyl-3-dodecanamido-4-(methylthio)benzamide in the form of white crystals, m.p. 126-128°C [Elemental analysis:- C,68.4;H,9.6;N,6.7;S,7.7%; calculated:-C,68.53;H,9.58;N,6.66;S,7.62%];
N-(2-methoxy)ethyl-3-dodecanamido-4-(methylthio)- benzamide in the form of white crystals, m.p. 113-115°C [Elemental analysis:- C,65.3;H,9.2;N,6.6;S,7.6%;
calculated:- C,65.37;H,9.06;N,6.63;S,7.59%];
N-(2-methylthio)ethyl-3-dodecanamido-4-(methylthio)-benzamide in the form of white needles, m.p. 102-104°C [Elemental analysis:- C,63.1;H,8.8;N,6.7;S,14.7%;
calculated:- C,62.97;H,8.73;N,6.39;S,14.62%]; and
N-butyl-N-methyl-3-hexadecanamido-4-methoxybenzamide in the form of an off-white powder [from petrol (b.p.
100-120°C)], m.p. 66-68°C [Elemental analysis:- C,73.2; H,10.8;N,5.61%; calculated:- C,73.37;H,10.62;N,5.90%].
EXAMPLE 6
Compound L
A solution of 1-decylcyclopentanecarboxylic acid (2.1g) and thionyl chloride (3ml) in dry dichloromethane (30ml) was heated at reflux for 3 hours. The reaction mixture was concentrated under reduced
pressure and the resulting residue was dissolved in dichloromethane (30ml) and added to a solution of dry triethylamine (2.4g) and N-(2-methylthio)ethyl-3-amino-4-(methylthio) benzamide (2.16g) in dichloromethane (50ml). The mixture was stirred at the ambient temperature for 1 hour, then it was diluted with dichloromethane (100ml) and washed sequentially with hydrochloric acid (100ml;1N), aqueous sodium chloride solution (100ml), aqueous potassium hydroxide solution (1.5g in 100ml), hydrochloric acid (100ml;1N) and with aqueous sodium chloride solution (100ml), dried over magnesium sulphate and concentrated under reduced pressure. The resulting residue was chromatographed on silica gel, eluting with t-butyl methyl ether, to give N-(2-methylthio)ethyl-3-(1-decylcyclopentanecarboxamido)-4-(methylthio)benzamide (3.15g) in the form of a waxy solid.
[Elemental analysis : - C, 66.2 ;H, 9.4 ;N, 5.24 ; S , 12.3% ;
calculated for C27H44N2O2S2:1/3:C5H12O:- C,65.94;H,9.27;N,5.36;S,12.28%].
EXAMPLE 7
Compounds M and N
A mixture of (Z)-methyl 4-methoxy-3-(octadec-9- enamido)benzoate (6.12g; prepared as described in
Example 3), sodium hydroxide (0.6g), water (20ml) and ethanol (200ml) was heated at reflux for 1.5 hours. The mixture [containing (Z)-sodium 4-methoxy-3-(octadec-9-enamido)benzoate] was cooled to the ambient temperature and was then poured onto a mixture of crushed ice and concentrated hydrochloric acid. The product was collected and recrystallised from methanol, to give (Z)-4-methoxy-3-(octadec-9-enamido)benzoic acid (4.14g) in the form of a white powder, m.p.
179-183 °C. [Elemental analysis : - C, 72.3 ; H, 9.5 ;
N,3.3%; calculated:- C,72.35;H,9.57;N,3.24%]. EXAMPLE 8
Compounds O to V
By proceeding in a manner similar to that described in Example 5, but employing the appropriate acid chlorides and the appropriate anilines, and simply removing the solvent under reduced pressure at the end of the reaction period and crystallising the residue , there were prepared:- N-butyl-3-dodecanamido-4-(ethylthio)benzamide, in the form of white plates, m.p. 102-104°C (from aqueous ethanol) [Elemental analysis:- C,69.0;H,9.9;N,6.4;
S,7.4%; calculated:- C,69.08;H,9.74;N,6.45;S,7.37%]; N-butyl-4-ethylthio-3-hexadecanamidobenzamide, in the form of white crystals, m.p. 89-91°C (from aqueous ethanol) [Elemental analysis:- C,70.9;H,10.3;N,5.4; S,6.57%; calculated:- C,70.97;H,10.27;N,5.71;S,6.53%]; N-butyl-4-ethylthio-3-heptadecanamidobenzamide, in the form of white crystals, m.p. 81-83°C (from aqeeous ethanol) [Elemental analysis:- C,71.1;H,10.7;N,5.3; S,6.09%; calculated:- C,71.37;H,10.38;N,5.55;S,6.35%]; N-butyl-4-ethylthio-3-octadecanamidobenzamide, in the form of white crystals, m.p. 80-82°C (from aqueous ethanol) [Elemental analysis:- C,71.6;H,10.8;N,5.3; S,6.02%; calculated:- C,71.76;H,10.49;N,5.40;S,6.18%]; 4-ethylthio-3-hexadecanamido-N-(2-methylthioethyl)- benzamide, in the form of white crystals, m.p. 92-94°C
(from aqueous ethanol) [Elemental analysis:- C,66.5;
H,9.7;N,5.5;S,12.5%; calculated:- C,66.09;H,9.51;
N,5.51;S,12.60%];
4-ethylthio-3-heptadecanamido-N-(2-methylthioethyl)- benzamide, in the form of white crystals, m.p. 91-93°C
(from aqueous ethanol) [Elemental analysis:- C,66.5;
H,9.7;N,5.36;S,12.0%; calculated:- C, 66.62;H,9.64;
N,5.36;S,12.26%];
3-heptadecanamido-4-methylthio-N-(2-methylthioethyl)- benzamide, in the form of white crystals, m.p.
101-102°C (from aqueous ethanol and then from ethyl acetate) [Elemental analysis:- C,66.5;H,9.8;N,5.50; S,12.6%; calculated:- C,66.09;H,9.51;N,5.51;S,12.60%]; and
3-heptadecanamido-N-(2-methoxyethy1)-4-(methylthio)-benzamide, in the form of white crystals, m.p.
115-116ºC (from aqueous ethanol and then from
isopropanol) [Elemental analysis:- C,68.4;H,10.10;
N,5.65;S,6.50%; calculated:- C,68.25;H,9.82;N,5.69; S,6.50%].
EXAMPLE 9
Compound W
By proceeding in a manner similar to that described in Example 2, but replacing the N-(2-methoxy)ethyl-3-amino-4-(methylthio)benzamide by the appropriate quantity of 3-amino-N-butyl-4-(methylthio)benzamide and crystallising the product from toluene, there was prepared (Z)-N-butyl-3-octadec-9-enamido-4-(methylthio)benzamide, in the form of a soft, pale brown solid, m.p. 118-120°C [Elemental analysis:-C,71.3;H,10.0;N,5.59;S,6.37%; calculated:- C,71.66;
H,10.02;N,5.57;S,6.38%].
EXAMPLE 10
Compounds X to AJ
By proceeding in a manner similar to that described in Example 5, but employing the appropriate acid chlorides and the appropriate anilines, there were prepared:-
4-ethylthio-N-(3-methyIthiopropyl)-3-octadecanamidobenzamide, in the form of colourless crystals, m.p. 75-76°C (from a mixture of t-butyl methyl ether and methanol) [Elemental analysis:- C,67.4;H,10.0;N,5.0; S,11.6%; calculated:- C,67.59;H,9.88;N,5.08;S,11.64%]; 4-ethylthio-3-heptadecanamido-N-(3-methyIthiopropyl)-benzamide, in the form of white crystals, m.p. 74-77°C (from a mixture of t-butyl methyl ether and methanol) [Elemental analysis:- C,67.5;H,10.00;N,5.30;S,11.70%; calculated:- C,67.11;H,9.76;N,5.22;S,11.95%];
4-ethylthio-3-hexadecanamido-N-(3-methyIthiopropyl)- benzamide, in the form of white crystals, m.p. 75-78°C (from a mixture of t-butyl methyl ether and methanol) [Elemental analysis:- C,66.5;H,9.7;N,5.11;S,11.9%; calculated:- C, 66.62;H, 9.64;N, 5.36;S, 12.26%];
4-methylthio-N-(2-methylthioethyl)-3-octadecanamidobenzamide, in the form of white crystals, m.p.
104-106ºC (from a mixture of t-butyl methyl ether and methanol) [Elemental analysis:- C,66.6;H, 9.9;N, 5.2; S,12.0%; calculated:- C,66.62;H,9.64;N,5.36;S,12.26%]; N-butyl-3-dodecanamido-4-methoxybenzamide, in the form of white crystals, m.p. 107-109°C (from t-butyl methyl ether) [Elemental analysis:- C,70.9;H,10.10;N,6.72%; calculated:- C,71.24;H,9.96;N,6.93%];
4-ethylthio-3-hexadecanamido-N-(3-methoxypropyl)benzamide, in the form of white crystals, m.p. 78-80°C (from acetonitrile) [Elemental analysis:- C,68.4;
H,9.93;N,5.1;S,6.21%; calculated:- C,68.73;H,9.94;
N,5.53;S,6.33%];
N-butyl-3-octadecanamido-4-(methylthio)benzamide, in the form of a white powder, m.p. 115-118°C (from a mixture of t-butyl methyl ether and methanol)
[Elemental analysis:- C,71.6;H,10.7;N,5.13;S,5.79%; calculated:- C,71.38;H,10.38;N,5.55;S,6.35%];
4-methylthio-N-(3-methyIthiopropyl)-3-octadecanamidobenzamide in the form of a white powder, m.p. 87-94°C (from toluene) [Elemental analysis:- C,66.6;H,9.85; N,4.83;S,11.65%; calculated:- C,67.12;H,9.76;N,5.22; 8,11.94%];
4-ethylthio-N-(3-methoxypropyl)-3-octadecanamidobenzamide, in the form of a white powder, m.p. 80-83°C (from toluene) [Elemental analysis:- C,69.7;H,10.3;
N,5.07;S,5.87%; calculated:- C,69.62;H,10.18;N,5.24; S,5.99%];
N-butyl-3-(5-chloropentanamido)-4-(ethylthio)benzamide, in the form of a white powder, m.p. 104-105°C (from t-butyl methyl ether) [Elemental analysis:- C,58.2;
H,7.4;Cl,9.6;N,7.5;S,8.6%; calculated:- C,58.28;H,7.34; Cl,9.56;N,7.55;S,8.64%];
3-(4-chlorobutanamido)-4-ethylthio-N-(3-methyIthiopropyl)benzamide in the form of a white powder, m.p. 80-81°C (from a mixture of t-butyl methyl ether and methanol) [Elemental analysis:- C, 52.2;H,6.87;Cl,9.5; N,7.3;S,15.7%; calculated:- C,52.49;H,6.48;Cl,9.11;
N,7.20;S,16.49%];
3-(5-chloropentanamido) -4-ethylthio-N-(3-methyIthiopropyl) benzamide, in the form of a pale yellow powder, m.p. 95-96°C (from a mixture of t-butyl methyl ether and methanol) [Elemental analysis:- C,53.7;H,6.87;
Cl,8.8;N,6.82;S,15.6%; calculated:- C,53.65;H, 6.75; Cl,8.80;N,6.85;S,15.91%]; and
methyl 3-hexadecanamido-4-methoxybenzoate, in the form of colourless needles, m.p. 109-110°C (from ethanol) [Elemental analysis:- C,71.1;H,9.9;N,3.26%;
calculated:- C,71.56;H,9.85;N,3.34%].
EXAMPLE 11
Compounds AK and AL
By proceeding in a manner similar to that described in Example 7 but replacing the (Z)-methyl 4-methoxy-3-(octadec-9-enamido)benzoate by the
corresponding quantity of methyl 3-hexadecanamido-4- methoxybenzoate (prepared as described in Example 10), there was prepared 3-hexadecanamido-4-methoxybenzoic acid, in the form of colourless needles, m.p. 198-200°C (from ethanol) [Elemental analysis:- C,71.1;H,9.8;
N,3.40%; calculated:- C,71.07;H,9.69;N,3.45%], via sodium 3-hexadecanamido-4-methoxybenzoate.
EXAMPLE 12
Compound AM
A mixture of 3-hexadecanamido-4-methoxybenzoic acid (4.04g; prepared as described in Example 11) and thionyl chloride (1.3ml) was heated in boiling toluene (100ml) for 3 hours. The solvent was removed under reduced pressure. The residual acid chloride was dissolved in dry dichloromethane (35ml) and was added to a stirred solution of 2-methoxyethylamine (3ml) and dry triethylamine (1.6ml) in dichloromethane (115ml). After standing at the ambient temperature for 2 days, the solution was washed with hydrochloric acid (2x200ml;2N) and then with water (2x200ml) and was then it was dried over potassium carbonate and concentrated under reduced pressure. The resulting residue was chromatographed on silica gel, eluting with a mixture of diethyl ether and dichloromethane, to give
3-hexadecanamido-4-methoxy-N-(2-methoxyethyl)benzamide (2.0g), in the form of a white powder, m.p. 78-80ºC
[Elemental analysis:- C,69.8;H,10.3;N,5.90%;
calculated:- C,70.09;H,10.02;N,6.06%].
EXAMPLE 13
Compound AN
A solution of 3-hexadecanamido-4-methoxybenzoyl chloride [prepared from 3-hexadecananamido-4-methoxybenzoic acid (2.02g; prepared as described in Example 11) and thionyl chloride] in dichloromethane (50ml) was added to a stirred solution of 3-methylbut-2-enylamine hydrochloride (0.98g) in dichloromethane (100ml) and triethylamine (1ml). The mixture was stirred at the ambient temperature for 1 hour and was then washed succesively with water (100ml), aqueous sodium
hydroxide solution (100ml;2N), dilute hydrochloric acid (100ml;2N) and with water (100ml), and it was then dried over magnesium sulphate and concentrated under reduced pressure . The resulting residue was
chromatographed on silica gel, eluting with a mixture of methanol and dichloromethane, to give 3-hexadec anamido-4-methoxy-N-(3-methylbut-2-enyl)benzamide (0.6g), in the form of a cream solid, m.p. 109-111°C after crystallisation from a mixture of petrol (b.p. 40-60°C) and diethyl ether [Elemental analysis:- C,73.2;H,10.3;N,5.60%; calculated:- C,73.68;H,10.24; N,5.93%].
EXAMPLE 14
Compounds AO to AZ
A solution of 5,9-dioxahexadecanoyl chloride in dichloromethane [prepared from 5,9-dioxahexadecanoic acid (2.0g; prepared as described in Example 17) and oxalyl chloride (2.4ml) in dichloromethane (25ml)] was added to a stirred suspension of 3-amino-N-butyl-4- (methylthio)benzamide (1.83g) in dry dichloromethane (25ml) and triethylamine (2.5g), producing a clear solution. After standing at the ambient temperature for 65 hours, the solution was concentrated under reduced pressure to about 10ml. The residue was taken up in t-butyl methyl ether (300ml) and was washed sequentially with dilute hydrochloric acid (100ml;
0.5N), aqueous sodium hydroxide solution (100ml;2%w/v) and with dilute hydrochloric acid (100ml;0.5N) and was then dried and concentrated under reduced pressure. The resulting residue was chromatographed on silica gel, eluting with ethyl acetate, to give N-butyl-4- methylthio-3-(5,9-dioxahexadecanamido)benzamide (2.05g) in the form of a pale yellow, waxy solid [Elemental analysis:- C,65.4;H,9.6;N,5.93;S,6.42%; calculated:-C,64.96;H,9.23;N,5.83;S,6.67%].
By proceeding in a similar manner, but using the appropriate acids and the appropriate anilines, there were prepared:- 4-methylthio-N-(3-methyIthiopropyl)-3-(5,9-dioxahexadecanamido)benzamide, in the form of a pale yellow, waxy solid [Elemental analysis:- C,61.0;H,8.9;N,5.36; S,12.4%; calculated:- C,60.90;H,8.65;N,5.46;S,12.51%]; N-butyl-4-ethylthio-3-(5,9,13-trioxahexadecanamido)-benzamide, in the form of an amber oil [Elemental analysis:- C,62.5;H,9.1;N,5.7;S,6.43%; calculated:-C,62.87;H,8.93;N,5.64;S,6.46%];
4-ethylthio-N-(3-methyIthiopropyl)-3-(5,9-dioxahexadecanamido)benzamide, in the form of a pale yellow, waxy solid (eluting with a mixture of dichloromethane and methanol) [Elemental analysis:- C,61.4;H,8.91;
N,5.34;S,12.0%; calculated:- C, 61.56;H,8.80;N,5.32; S,12.17%];
N-butyl-4-ethylthio-3-(5,9-dioxahexadecanamido)-benzamide, in the form of a pale brown oil (eluting with a mixture of dichloromethane and methanol)
[Elemental analysis:- C,65.4;H,9.6;N,5.5;S,6.26%;
calculated:- C,65.55;H,9.37;N,5.66;S,6.48%]; 4-ethylthio-N-(3-methoxypropyl)-3-(5,9-dioxahexadecanamido)benzamide, in the form of a pale brown oil (eluting with a mixture of dichloromethane and
methanol) [Elemental analysis:- C,63.2;H,9.1;N,5.2; S,6.12%; calculated:- C,63.50;H,9.08;N,5.48;S,6.28%]; 4-ethylthio-N-(3-methoxypropyl)-3-(5,9,13-trioxahexadecanamido)benzamide, in the form of a pale brown oil [Elemental analysis:- C,60.5;H,8.7;N,5.16;S,6.08%;
calculated:- C,60.91;H,8.65;N,5.46;S,6.25%];
4-ethylthio-N-(3-methoxypropyl)-3-(5-oxahexadecanamido)benzamide, in the form of a pale brown oil that solidified on standing (eluting with a mixture of dichloromethane and methanol) [Elemental analysis:- C,66.4;H,9.8;N,5.35;S,6.24%; calculated:- C,66.10;
H,9.51;N,5.51;S,6.30%];
4-methylthio-N-(3-methyIthiopropyl)-3-(5-oxahexadecanamido) benzamide, in the form of a pale brown oil that solidified on standing (eluting with a mixture of dichloromethane and methanol) [Elemental analysis:-C,63.6;H,9.3;N,5.48;S,11.9%; calculated:-C,63.49;H,9.08;N,5.17;S,12.55%];
N-butyl-4-methylthio-3-(5-oxahexadecanamido)benzamide, in the form of a pale brown oil that solidified on standing (eluting with a mixture of dichloromethane and methanol) [Elemental analysis:- C,68.0;H,9.9;N,5.6; S,6.24%; calculated:- C, 67.74;H,9.69;N,5.85;S,6.70%]; 4-methoxy-N-(3-methyIthiopropyl)-3-(5,9-dioxahexadecanamido)benzamide, in the form of a pale brown oil (eluting with a mixture of dichloromethane and
methanol) [Elemental analysis:- C,62.5;H,9.2;N,5.48; S,6.19%; calculated:- C,62.87;H,8.93;N,5.64;S,6.46%]; and
4-ethylthio-N-(3-methyIthiopropyl)-3-(5,9,13-trioxahexadecanamido)benzamide, in the form of a pale brown oil (eluting with a mixture of dichloromethane and methanol) [Elemental analysis:- C,58.2;H,8.5;N,4.96; S,11.3%; calculated:- C,59.06;H,8.39;N,5.30;S,12.13%].
EXAMPLE 15
Compound BA
Heptadecanoyl chloride (2.79g) was added dropwise during 10 minutes to a stirred solution of methyl 3-amino-4-(imidazol-1-yl)benzoate (2.0g;
prepared as described in Reference Example 1) in dry pyridine (60ml). When the reaction was complete (judging by a thin-layer chromatogram), water (300ml) was added. The precipitated solid was collected, washed with water and dried and was then dissolved by heating in ethyl acetate (60ml) containing hydrochloric acid (1ml). The solid which crystallised on cooling was collected, was washed with diethyl ether and was dried at 80°C, to give methyl 3-heptadecanamido-4- (imidazol-1-yl)benzoate in the form of white crystals of the hydrated hydrochloride, m.p. 106-109°C
[Elemental analysis:- C,64.7;H,8.6;N,7.9;Cl,6.83;water, 3.8%; calculated for C28H43N3O3.HCl.H2O:- C,64.72;
H,8.99;N,7.81;Cl,6.59;water, 3.35%].
EXAMPLE 16
Compounds BB to BG
By the application or adaptation of methods described hereinbefore, more especially in the
preceding Examples, there were prepared:-N-(3-methylsulphonylpropyl)-4-methylthio-3-(5,9-dioxahexadecanamido)benzamide, in the form of a pale brown oil which solidified on standing;
4-ethylthio-N-(3-methyIthiopropyl)-3-(5,9-dioxaoctadecanamido)benzamide, in the form of a pale brown oil
[Elemental analysis:- C,63.1;H,9.5;N,4.37%;
calculated:- C,62.78;H,9.08;N,5.05%];
N-butyl-4-ethylthio-3-(5,10-dioxahexadecanamido)-benzamide, in the form of a pale yellow solid;
4-ethylthio-N-(3-methyIthiopropyl)-3-(6,10,14-trioxahexadecanamido)benzamide, in the form of a pale brown oil [Elemental analysis:- C,58.0;H,8.5;N,5.30; S,11.0%; calculated:- C,59.06;H,8.39;N,4.95;S,12.13%]; 4-imidazol-1-yl-N-(3-methyIthiopropyl)-3-(5-oxahexadecanamido)benzamide, in the form of a white powder, m.p. 77-79°C [Elemental analysis:- C,66.0;H,8.9;
N,10.7%; calculated:- C,65.62;H,8.74;N,10.56%]; and 3-hexadecanamido-4-imidazol-1-yl-N-(3-methyIthiopropyl)benzamide, in the form of a white powder, m.p. 104-105°C [Elemental analysis:- C,68.6;H,9.4;N,10.7%; calculated: - C,68.14;H,9.15;N,10.60%]. EXAMPLE 17
Compounds INT a, INT b and INT c
Sodium bromite trihydrate (35.0g) was added to a cooled, vigorously stirred mixture of 5,9,13-trioxahexadecan-1-ol (11.5g), 2,2,6, 6-tetramethyl-1-piperidinyloxy, free radical (0.25g), aqueous sodium hydrogen carbonate solution (450ml;5%w/v) and acetonitrile
(450ml) maintaining a temperature of from 0°C to 10°C. The mixture was stirred at the ambient temperature for 4 hours and then the reaction was quenched by the careful addition of sufficient hydrochloric acid and aqueous sodium metabisulphite to give a pH of from 2 to 4 and to consume excess oxidant. The solution was extracted with t-butyl methyl ether (4x200ml) and the combined organic solution was washed with aqueous sodium chloride solution, dried and concentrated under reduced pressure. The resulting residue was
distilled at an oven temperature of 170°C and a
pressure of 0.1mmHg, to give 5,9,13-trioxahexadecanoic acid (10.3g) in the form of a colourless, mobile oil. [Elemental analysis:- C,59.52;H,9.99%; calculated:= C,59.9;H,10.9%].
By proceeding in a similar manner, but replacing the 5,9,13-trioxahexadecan-1-ol by the appropriate quantities of 5,9-dioxahexadecan-1-ol and 5-oxahexa decan-1-ol, respectively, and with the difference that the residue left after concentrating under reduced pressure was taken up in t-butyl methyl ether, filtered to remove solids, and concentrated under reduced pressure again before distilling, there were prepared:-5,9-dioxahexadecanoic acid, in the form of a
colourless, mobile oil [Elemental analysis:- C,64.9; H,11.3%; calculated:- C,64.58;H,10.84%]; and
5-oxahexadecanoic acid, in the form of a colourless, mobile oil which solidified, m.p. 28-30°C [Elemental analysis:- C,68.5;H,11.6%; calculated:-C,69.72;H,11.70%].
EXAMPLE 18
Compounds INT d, INT e and INT f
By proceeding in a manner similar to that described in Example 17, but using the appropriate alcohols, there were prepared:-
6,10,14-trioxahexadecanoic acid, in the form of a colourless, mobile oil [Elemental analysis:- C,57.5; H,10.0%; calculated:- C,59.52;H,9.99%];
5,10-dioxahexadecanoic acid, in the form of a colourless, mobile oil, b.p. 97-105°C/0.1mmHg
[Elemental analysis:- C,66.1;H, 11.5%; calculated:-C,64.58;H,10.84%]; and
5,9-dioxahexadecanoic acid, in the form of a
colourless, mobile oil [Elemental analysis:- C,66.2; H,11.4%; calculated:- C,66.63;H,11.18%].
REFERENCE EXAMPLE 1
Methyl 4-(imidazol-1-yl)-3-nitrobenzoate (19.3g) was reduced by reaction with iron powder (22. Og) in boiling ethanol (150ml) containing water (35ml) and hydrochloric acid (1.5ml;1N). Recrystallisation from ethyl acetate gave methyl 3-amino-4-(imidazol-1-yl)-benzoate (9.7g) in the form of pale yellow crystals, m.p. 161-165°C.
REFERENCE EXAMPLE 2
Methyl 4-fluoro-3-nitrobenzoate (17.0g) was reacted with imidazole (13.0g) at the ambient
temperature in dry tetrahydrofuran (100ml), to give methyl 4-(imidazol-1-yl)-3-nitrobenzoate (14.68g) in the form of large yellow needles, m.p. 71-74°C (from t-butyl methyl ether).
REFERENCE EXAMPLE 3
4-Ethylthio-N-(3-methoxypropyl)-3-nitrobenzamide (47.0g) was reduced by reaction with iron powder
(55.0g) in boiling ethanol (750ml) containing
hydrochloric acid (95ml;0.5N). Recrystallisation from t-butyl methyl ether gave 3-amino-4-ethylthio-N-(3-methoxypropyl)benzamide (32.4g) in the form of fine cream needles, m.p. 73-75°C.
REFERENCE EXAMPLE 4
Reaction of 3-methoxypropylamine with
4-ethylthio-3-nitrobenzoyl chloride and recrystallisation from toluene gave
4-ethylthio-N-(3-methoxypropyl)-3-nitrobenzamide in 74% yield in the form of a yellow solid, m.p.
101-103°C.
REFERENCE EXAMPLE 5
A solution of 3-(3-propoxypropoxy)propan-1-ol (25.39g) and dry pyridine (11.47g) in dichloromethane (30ml) was added during 10 minutes to a stirred
solution trifluoromethanesulphonic anhydride (49.1g) in dichloromethane (90ml), keeping the temperature below 0ºC. The mixture was stirred for 3 hours without further cooling and was then washed with ice-cold water (100ml) and dried. The solution was filtered, diluted with dichloromethane (150ml) and was then stirred with potassium carbonate (27.0g) and
4-hydroxybutyl acrylate (25.2g) overnight at ambient temperature under an atmosphere of argon. The mixture was then heated at reflux for 8 hours. The mixture was filtered, the residue was washed with
dichloromethane (300ml) and the filtrate was then washed with hydrochloric acid (250ml;1N) and with water (2x250ml). The residue left after drying and
concentrating under reduced pressure was dissolved in ethanol (300ml) and was stirred with a solution of sodium hydroxide (11.4g) in water (65ml) for 4 hours. The solution was concentrated under reduced pressure to about 180ml, was diluted with t-butyl methyl ether (llitre) and was washed with water (2x400ml). The residue left after drying and concentrating under reduced pressure was distilled under reduced pressure to give 5,9,13-trioxahexadecan-1-ol (16.9g) in the form of a colourless, mobile oil, b.p. 109-113ºC/0.1mmHg.
By proceeding in a similar manner, but using the appropriate quantity of 3-heptyloxypropan-1-ol instead of 3-(3-propoxypropoxy)propan-1-ol, there was prepared 5,9-dioxahexadecan-1-ol, in the form of a colourless, mobile oil, b.p. 123-125°C/0.1mmHg.
REFERENCE EXAMPLE 6
Lithium aluminium hydride (3.5g) was carefully added to a stirred solution of aluminium chloride
(38.98g) .in diethyl ether (200ml) under a gentle stream of nitrogen, keeping the temperature below 15°C. The mixture was stirred for 2 hours and then 2-decyl-1,3-dioxepane (30.7g) was added during 30 minutes. The mixture was stirred at reflux for 8 hours and was then cooled to ambient temperature. Water (50ml) was added dropwise, followed by diethyl ether (300ml). The aqueous fraction was extracted with diethyl ether
(3x200ml) and the combined organic solution was then dried. The solvent was removed and the residue was distilled, to give 5-oxahexadecan-1-ol (25.24g) in the form of an oil, b.p. 126-127°C/0.1mmHg. The present invention also includes within its scope pharmaceutical formulations which comprise at least one of the compounds of formula I, or a
pharmaceutically acceptable salt thereof, in
association with a pharmaceutically acceptable carrier or coating. In clinical practice the compounds of the present invention may be administered parenterally, rectally or orally.
Solid compositions for oral administration include compressed tablets, pills, powders and
granules. In such solid compositions, one or more of the active compounds is, or are, admixed with at least one inert diluent such as starch, sucrose or lactose. The compositions may also comprise, as is normal practice,, additional substances other than inert diluents, e.g. lubricating agents, such as magnesium stearate.
Liquid compositions for oral administration include pharmaceutically acceptable emulsions,
solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art such as water and liquid paraffin. Besides inert diluents such compositions may comprise adjuvants, such as wetting and suspending agents, and sweetening, flavouring, perfuming and preserving agents. The compositions according to the invention for oral administration also include capsules of absorbable material such as
gelatin, containing one or more of the active
substances with or without the addition of diluents or excipients.
Preparations according to the invention for parenteral administration include sterile aqueous, aqueous-organic, and organic solutions, suspensions and emulsions. Examples of organic solvents or suspending media are propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate. The compositions may also contain adjuvants such as stabilising, preserving, wetting, emulsifying and dispersing agents. They may be sterilised, for example, by filtration through a bacteria-retaining filter, by incorporation in the compositions of sterilising agents, by irradiation or by heating. They may also be manufactured in the form of sterile solid compositions, which can be dissolved in sterile water or some other sterile injectable medium immediately before use.
Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of formula I.
The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired
therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.5 to about 70, preferably about 1 to about 10, mg/kg body weight per day by oral administration.
The following Example illustrates pharmaceutical compositions according to the present invention.
COMPOSITION EXAMPLE 1
No. 2 size gelatin capsules each containing:- N-butyl-3-hexadecanamido-4-(methylthio)- benzamide; 20 mg lactose 100 mg starch 60 mg dextrin 40 mg magnesium stearate 1 mg were prepared in accordance with the usual procedure.

Claims

1. A benzamide derivative of the formula:
wherein R1 represents a straight- or branched-chain alkyl group containing up to 20 carbon atoms, optionally
containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups, optionally carrying one or more substituents selected from halogen atoms, amino groups, alkoxy, alkylthio and alkylamino groups each containing up to 3 carbon atoms and groups of the formula -CONR6R7 wherein R6 represents a hydrogen atom or a methyl group and R7 represents a methyl, trifluoromethyl or trichloromethyl group, the symbols R2 are the same or different and each represents a hydrogen atom, a straight- or branched-chain alkyl group containing up to 6 carbon atoms or an
optionally substituted phenyl group or the two groups R2 together with the carbon atom to which they are attached form a saturated or unsaturated ring containing from 3 to 8 carbon atoms and optionally containing one or more hetero atoms selected from oxygen, sulphur and nitrogen atoms, R3 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to 6 carbon atoms, R4 represents a straight- or branched-chain alkoxy or alkylthio group containing up to 6 carbon atoms or a dimethylamino group or a 5- to 8-membered heterocyclo group containing at least one nitrogen atom and linked via that nitrogen atom to the rest of the molecule, and R5 represents a group of the formula -NR8R9 or -OR10 wherein R8 and R9 may be the same or different and each represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to 10 carbon atoms, optionally containing one or more carboncarbon double or triple bonds, and optionally interrupted by one or more hetero atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups, and R10
represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups, and pharmaceutically acceptable salts thereof.
2. A compound according to claim 1 wherein R1 represents an alkylthioalkyl, alkylaminoalkyl or
dialkylaminoalkyl group.
3. A compound according to claim 1 wherein R1 represents an alkyl, alkenyl, alkoxyalkyl,
alkoxyalkoxyalkyl or alkoxyalkoxyalkoxyalkyl group.
4. A compound according to any one of the preceding claims wherein the heterocyclo group represented by R4 is an imidazol-1-yl or pyrrolidin-1-yl group.
5. A compound according to claim 1 wherein at least one of the symbols has a value selected from the following:-
(i) R1 represents an alkyl, alkenyl, alkoxyalkyl,
alkoxyalkoxyalkyl, alkoxyalkoxyalkoxyalkyl or haloalkyl group, containing from 8 to 20 carbon atoms;
(ii) the symbols R2 each represent a hydrogen atom, or the two groups R2 together with the carbon atom to which they are attached form a cycloalkyl ring containing from 3 to 8 carbon atoms;
(iii) R3 represents a hydrogen atom;
(iv) R4 represents an imidazol-1-yl group or a
straight- or branched-chain alkoxy or alkylthio group containing up to 3 carbon atoms;
(v) R8 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to 3 carbon atoms;
(vi) R9 represents a straight- or branched-chain alkyl or alkenyl group containing up to 6 carbon atoms, optionally interrupted by one or more oxygen or sulphur atoms or sulphonyl groups;
(vii) R10 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to 6 carbon atoms, the other symbols being as defined in claim 1.
A compound according to claim 5 wherein
(i) R1 represents an alkyl or alkenyl group
containing from 8 to 20 carbon atoms;
(ii) the cycloalkyl ring represented by the two groups
R2 together with the carbon atom to which they are attached contains 5 or 6 carbon atoms;
(iv) the alkoxy or alkylthio group represented by R4 contains 1 or 2 carbon atoms;
(v) R8 represents hydrogen or methyl;
(vi) R9 represents an alkyl, alkoxyalkyl or
alkylthioalkyl group containing 3 or 4 carbon atoms or an alkenyl group containing 5 carbon atoms;
(vii) R10 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to 3 carbon atoms.
7. A compound according to claim 5 or 6 wherein
(i) R1 represents an alkyl or alkenyl group
containing from 10 to 18 carbon atoms;
(ii) the cycloalkyl ring represented by the two groups R2 together with the carbon atom to which they are attached contains 5 carbon atoms;
(iv) the alkoxy or alkylthio group represented by R4 is methoxy, methylthio or ethylthio;
(vi) R9 represents a butyl, methoxyethyl,
methylthioethyl, methoxypropyl, methylthiopropyl, methylsulphonylpropyl or methylbut-2-enyl group;
(vii) R10 represents a hydrogen atom or a methyl group.
8. A benzamide derivative according to claim 1 hereinbefore identified as any one of compounds A to BG or a pharmaceutically acceptable salt thereof.
9. A process for the preparation of a compound according to claim 1 which comprises:
(A) the reaction of a compound of the general
formula:
II
wherein R3, R4 and R5 are as defined in claim 1, with a compound of the general formula :
R1-C(R2)2COZ1 III wherein R1 and R2 are as defined in claim 1 and Z1 represents a halogen atom or an alkoxycarbonyloxy group, or with the corresponding anhydride of the general formula :
[R1-C(R2)2CO]2O IV wherein R1 and R2 are as defined in claim 1, or
(B) when R5 is other than a group OR10 in which R10 is hydrogen, the reaction of a compound of general formula
R11OH V wherein R11 represents a straight- or branched-chain alkyl group containing up to 10 carbon atoms, optionally
containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups, or a compound of general formula :
HNR8R9 VI wherein R8 and R9 are as defined in claim 1, with a
compound of the general formula : VII
wherein R1, R2, R3 and R4 are as hereinbefore defined and Z2 represents a hydroxy group, a halogen atom or an
alkoxycarbonyloxy group, or with the corresponding
anhydride;
(C) optionally followed by the conversion by known methods of a compound of general formula (I) into another compound of general formula (I)
(D) optionally followed by conversion into a
pharmaceutically acceptable salt.
10. A pharmaceutical composition which comprises a benzamide derivative of general formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier or coating.
11. A pharmaceutical composition useful in the treatment of a condition which can be ameliorated by an inhibitor of acyl coenzyme-A:cholesterol-O-acyl transferase which comprises a benzamide derivative of general formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier or coating.
12. A method for the treatment of a condition which can be ameliorated by an inhibitor of acyl
coenzyme-A:cholesterol-O-acyl transferase which comprises the administration of a benzamide derivative of general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof.
13. A compound of the general formula:
R12-C(R2)2COOH IX wherein R12 represents an alkoxyalkyl, alkoxyalkoxyalkyl or alkoxyalkoxyalkoxyalkyl group and R2 is as defined in claim 1.
14. A process for the preparation of a compound as claimed in claim 13 which comprises the oxidation of a compound of the general formula :
R12-C(R2)2CH2OH X wherein R2 is as defined in claim 1 and R12 is as defined in claim 13, to convert the group -CH2OH to a group -COOH.
EP91914392A 1990-08-13 1991-08-13 Benzamide derivatives Withdrawn EP0543865A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9017711 1990-08-13
GB909017711A GB9017711D0 (en) 1990-08-13 1990-08-13 New compositions of matter

Publications (1)

Publication Number Publication Date
EP0543865A1 true EP0543865A1 (en) 1993-06-02

Family

ID=10680576

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91914392A Withdrawn EP0543865A1 (en) 1990-08-13 1991-08-13 Benzamide derivatives

Country Status (10)

Country Link
EP (1) EP0543865A1 (en)
JP (1) JPH06500315A (en)
AU (1) AU8427591A (en)
CA (1) CA2089151A1 (en)
GB (1) GB9017711D0 (en)
IE (1) IE912848A1 (en)
IL (1) IL99159A0 (en)
PT (1) PT98666A (en)
WO (1) WO1992003412A2 (en)
ZA (1) ZA916338B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2894445B2 (en) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Compounds effective as CETP activity inhibitors
CA2519458A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
US11021430B2 (en) * 2016-04-05 2021-06-01 Moresco Corporation Oxa acid compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2476074A1 (en) * 1979-12-13 1981-08-21 Lilly Co Eli Acylated amino poly:cyclic peptide antibiotics - useful for controlling fungal infections
US4500714A (en) * 1981-10-15 1985-02-19 Chugai Seiyaku Kabushiki Kaisha 3-Substituted-ureido-N-pyridyl benzamides
US4536346A (en) * 1983-05-06 1985-08-20 American Cyanamid Company Aralkanamidophenyl compounds
IT1196348B (en) * 1984-11-29 1988-11-16 Italfarmaco Spa COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY
DE3668450D1 (en) * 1985-03-14 1990-03-01 Smithkline Dauelsberg 5-AMINOSALICYL ACID DERIVATIVES OF NON-STEROIDAL ANTI-FLAMMABLE ACIDS.
EP0318859A3 (en) * 1987-12-03 1990-08-16 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9203412A2 *

Also Published As

Publication number Publication date
CA2089151A1 (en) 1992-02-14
WO1992003412A3 (en) 1992-04-30
AU8427591A (en) 1992-03-17
PT98666A (en) 1992-06-30
IL99159A0 (en) 1992-07-15
JPH06500315A (en) 1994-01-13
GB9017711D0 (en) 1990-09-26
ZA916338B (en) 1992-05-27
WO1992003412A2 (en) 1992-03-05
IE912848A1 (en) 1992-02-26

Similar Documents

Publication Publication Date Title
US5412145A (en) P2'-modified hydroxamic acid collagenase inhibitors
US5514716A (en) Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
US5700838A (en) Hydroxamic acid derivatives as metalloproteinase inhibitors
US5821262A (en) Hydroxamic acid derivatives as inhibitors of cytokine production
AU652088B2 (en) Chemical compounds
AU645935B2 (en) Production of fluoxetine and new intermediates
US5708033A (en) Amide derivatives and their therapeutic use
EP1484301B1 (en) PROCESS FOR PRODUCING trans-4-AMINO-1-CYCLOHEXANECARBOXYLIC ACID DERIVATIVE
PL209113B1 (en) Novel cyclohexyl sulphones
GB2174702A (en) Cyclopentyl ethes and their preparation and pharmaceutical formulation
US5159114A (en) Acat inhibitory benzanilides
EP0543865A1 (en) Benzamide derivatives
US20060135785A1 (en) Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof
IE910522A1 (en) Nitric acid esters of cyclohexanol derivatives, processes¹for the preparation thereof and pharmaceutical compositions¹containing them
US5917090A (en) Matrix metalloproteinase inhibitors
WO1997002239A1 (en) Matrix metalloproteinase inhibitors
EP0156279A2 (en) A novel process for the preparation of bestatin derivatives and intermediates thereof
US5530145A (en) Anticholesteremic compounds
AU732796B2 (en) Metalloproteinase inhibitors
US6436973B1 (en) LTA4 hydrolase inhibitors
US6197811B1 (en) Cytokine production inhibitors
EP0569482B1 (en) Synthesis of intermediates in the preparation of acat inhibitors
CA2103600A1 (en) Isobutyl-substituted methanesulphonyl- quinolyl-methoxyphenyl-cycloalkylacetamides
JPH10231280A (en) Production of 3-amino-2-hydroxy-4-phenylbutylonitrile derivatives
FI66863C (en) FRAMEWORK FOR THE FRAMSTATION OF THIAZOLIDIN-4-ONAETTYXYRADERIVAT

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19941005

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950419